10 powodów, dla których warto stosować lek złożony zawierający timolol i dorzolamid w terapii jaskry Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2017
Słowa kluczowe:
jaskra, timolol, dorzolamid, leki złożone, farmakoterapia jaskry
##plugins.themes.bootstrap3.article.main##
Abstrakt
Jaskra pierwotna otwartego kąta jest jedną z głównych przyczyn nieodwracalnej utraty widzenia w krajach rozwiniętych. Do zaawansowanych stadiów nie daje objawów, dlatego często pozostaje nierozpoznana aż do momentu znacznej utraty ostrości wzroku. Głównym czynnikiem ryzyka jaskry jest podwyższone ciśnienie wewnątrzgałkowe. Wszystkie metody leczenia jaskry o udowodnionej skuteczności, chroniące obumieranie nerwu wzrokowego, polegają na jego obniżaniu poprzez zastosowanie kropli, laseroterapii lub zabiegów chirurgicznych. Rozwój farmakoterapii wiąże się z wprowadzeniem nowych klas leków, a także ze stosowaniem preparatów złożonych. Pierwszym wprowadzonym na rynek preparatem złożonym było połączenie timololu i dorzolamidu, mające wiele zalet dla pacjentów z jaskrą.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Kosior-Jarecka, E. (2017). 10 powodów, dla których warto stosować lek złożony zawierający timolol i dorzolamid w terapii jaskry . Medycyna Faktów , 10(4(37), 352-356. https://doi.org/10.24292/01.MF.0417.9
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Fechtner R.D., Realini T.: Fixed combinations of topical glaucoma medications. Curr. Opin. Ophthalmol. 2004; 15(2): 132-135.
2. Inoue K., Shiokawa M., Sugahara M. et al.: Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn. J. Ophthalmol. 2012; 56(6): 559-563.
3. Fechtner R.D., Airaksinen P.J., Getson A.J. et al.; COSOPT versus XALATAN Study Groups: Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol. Scand. 2004; 82(1): 42-48.
4. Cheng J.W., Cheng S.W., Gao L.D. et al.: Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One 2012; 7(9): e45079.
5. Crichton A.C., Harasymowycz P., Hutnik C.M. et al.: Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J. Ocul. Pharmacol. Ther. 2010; 26(5): 503-511.
6. Ormrod D., McClellan K.: Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000; 17(6): 477-496.
7. Caprioli J., Coleman A.L.: Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008; 115(7): 1123-1129.
8. Bengtsson B., Leske M.C., Hyman L., Heijl A.; Early Manifest Glaucoma Trial Group: Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(2): 205-209.
9. Kass M.A., Gordon M.O., Gao F. et al.; Ocular Hypertension Treatment Study Group: Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch. Ophthalmol. 2010; 128(3): 276-287.
10. Pasquale L.R.: Optimizing therapy for newly diagnosed open-angle glaucoma: lessons learned from the Collaborative Initial Glaucoma Treatment Study. Arch. Ophthalmol. 2008; 126(1): 125-127.
11. Noecker R., Miller K.V.: Benzalkonium chloride in glaucoma medications. Ocul. Surf. 2011; 9(3): 159-162.
12. Ayaki M., Iwasawa A., Niwano Y.: Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride. Biocontrol. Sci. 2012; 17(3): 115-120.
13. Joseph A., Pasquale L.R.: Attributes Associated with Adherence to Glaucoma Medical Therapy and its Effects on Glaucoma Outcomes: An Evidence- Based Review and Potential Strategies to Improve Adherence. Semin. Ophthalmol. 2017; 32(1): 86-90.
14. Li T., Lindsley K., Rouse B. et al.: Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology 2016; 123(1): 129-140.
15. Sena D.F., Lindsley K.: Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. Rev. 2013; (2): CD006539.
16. Hartleben-Matkin C., Prada D., Mancilla-Vences R.: A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG. Int. J. Ophthalmol. 2014; 7(2): 330-334.
17. Tanna A.P., Lin A.B.: Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr. Opin. Ophthalmol. 2015; 26(2): 116-120.
18. Sng C.C., Ang M., Barton K.: Uveitis and glaucoma: new insights in the pathogenesis and treatment. Prog. Brain Res. 2015; 221: 243-269.
19. Turk A., Ceylan O.M., Gokce G. et al.: Comparison of brimonidine-timolol and dorzolamide-timolol in the management of intraocular pressure increase after phacoemulsification. Int. J. Ophthalmol. 2015; 8(5): 945-949.
2. Inoue K., Shiokawa M., Sugahara M. et al.: Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn. J. Ophthalmol. 2012; 56(6): 559-563.
3. Fechtner R.D., Airaksinen P.J., Getson A.J. et al.; COSOPT versus XALATAN Study Groups: Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol. Scand. 2004; 82(1): 42-48.
4. Cheng J.W., Cheng S.W., Gao L.D. et al.: Intraocular pressure-lowering effects of commonly used fixed-combination drugs with timolol: a systematic review and meta-analysis. PLoS One 2012; 7(9): e45079.
5. Crichton A.C., Harasymowycz P., Hutnik C.M. et al.: Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J. Ocul. Pharmacol. Ther. 2010; 26(5): 503-511.
6. Ormrod D., McClellan K.: Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma. Drugs Aging. 2000; 17(6): 477-496.
7. Caprioli J., Coleman A.L.: Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008; 115(7): 1123-1129.
8. Bengtsson B., Leske M.C., Hyman L., Heijl A.; Early Manifest Glaucoma Trial Group: Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007; 114(2): 205-209.
9. Kass M.A., Gordon M.O., Gao F. et al.; Ocular Hypertension Treatment Study Group: Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch. Ophthalmol. 2010; 128(3): 276-287.
10. Pasquale L.R.: Optimizing therapy for newly diagnosed open-angle glaucoma: lessons learned from the Collaborative Initial Glaucoma Treatment Study. Arch. Ophthalmol. 2008; 126(1): 125-127.
11. Noecker R., Miller K.V.: Benzalkonium chloride in glaucoma medications. Ocul. Surf. 2011; 9(3): 159-162.
12. Ayaki M., Iwasawa A., Niwano Y.: Comparative study of in vitro ocular surface cytotoxicity of a fixed combination of 0.5% timolol/1% dorzolamide eyedrop and its components with 0.005% benzalkonium chloride. Biocontrol. Sci. 2012; 17(3): 115-120.
13. Joseph A., Pasquale L.R.: Attributes Associated with Adherence to Glaucoma Medical Therapy and its Effects on Glaucoma Outcomes: An Evidence- Based Review and Potential Strategies to Improve Adherence. Semin. Ophthalmol. 2017; 32(1): 86-90.
14. Li T., Lindsley K., Rouse B. et al.: Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis. Ophthalmology 2016; 123(1): 129-140.
15. Sena D.F., Lindsley K.: Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst. Rev. 2013; (2): CD006539.
16. Hartleben-Matkin C., Prada D., Mancilla-Vences R.: A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG. Int. J. Ophthalmol. 2014; 7(2): 330-334.
17. Tanna A.P., Lin A.B.: Medical therapy for glaucoma: what to add after a prostaglandin analogs? Curr. Opin. Ophthalmol. 2015; 26(2): 116-120.
18. Sng C.C., Ang M., Barton K.: Uveitis and glaucoma: new insights in the pathogenesis and treatment. Prog. Brain Res. 2015; 221: 243-269.
19. Turk A., Ceylan O.M., Gokce G. et al.: Comparison of brimonidine-timolol and dorzolamide-timolol in the management of intraocular pressure increase after phacoemulsification. Int. J. Ophthalmol. 2015; 8(5): 945-949.